Post Location: Digital Biology and Biosecurity

Biotech Firm Revolutionizing Amino-Acid Manufacturing Closes $12 Million Series A Financing Round

SAN LEANDRO, CA — Aralez Bio, a platform technology company with a proprietary enzymatic approach for designing and manufacturing noncanonical amino acids (ncAAs), announced the close of its oversubscribed $12 million Series A financing today. The round was led by Spero Ventures with matched investment from Paladin Capital Group. Additional investors included Good Growth Capital, Astia […]

General Inception Launches Igniter Europe

To leverage the unique European life sciences ecosystem and establish differentiated deeptech companies with the support of leading institutions and venture capital firms. Lyon and San Francisco – April 30, 2024: General Inception announces the launch of Igniter Europe, focused on building innovative companies in the field of oncology, autoimmune and rare diseases, with novel […]

Partillion Bioscience Corporation Announces Seed Financing, Expanded Board, and New Partnership with Alloy Therapeutics

Financing will fund growth and expansion of new functional single-cell analysis and sorting product lines for drug discovery, enabled by Partillion’s proprietary Nanovial technology. Partillion Bioscience Corporation (“Partillion”), a life science tools company, today announced the closing of a $5 million seed financing round, expansion of its board of directors, and a multiyear agreement with Alloy Therapeutics, […]

Paladin Capital Group Named “2022 Founder-Friendly Investor” by Inc. Magazine

WASHINGTON – Today, Paladin Capital Group—a leading investor in early-stage cyber and other advanced technologies—was named to Inc. Magazine’s “2022 Founder-Friendly Investor” list, which recognizes investment partners that build trust and collaboration with entrepreneurs while accelerating growth. The competitive process recognizes private equity and venture capital firms that are endorsed by their portfolio companies. “Paladin […]

Paladin experts debate startups and investing

As founding CEO of the UK’s National Cyber Security Centre, Ciaran Martin brought an entrepreneurial mindset to the heart of government. In this #Paladinexperts video, Ciaran shares his passion for the role of startups in meeting the cyber challenge and creating technologies that are of “dual use” – valuable to both government and the private […]

Inscripta Announces the First Commercial Shipment of Its Onyx™ Digital Genome Engineering Platform and Closes $150 Million in New Financing

Inscripta, Inc., the digital genome engineering company, today announced the first commercial shipment of its Onyx™ platform and the closing of a $150 million Series E financing round led by Fidelity Management & Research Company LLC and funds and accounts advised by T. Rowe Price Associates, Inc. Among the first organizations to receive the Onyx platform […]

Paladin Portfolio Company, Inscripta, Raises $125 Million in Series D Financing

Inscripta, the genome editing company that recently launched a benchtop instrument for genome-scale engineering, said today it has raised $125 million in Series D financing, bringing its total capital raised to $259.5 million. Inscripta said it would use proceeds from the financing to accelerate applications expansion and commercialization of the company’s Onyx™ Digital Genome Engineering […]

10x Genomics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

PLEASANTON, Calif., Sept. 16, 2019 — 10x Genomics (Nasdaq: TXG) today announced the closing of its initial public offering of 11,500,000 shares of its Class A common stock, which includes the exercise in full of the underwriters’ option to purchase 1,500,000 additional shares of its Class A common stock, at a public offering price of $39.00 per share. Including the […]

Inscripta Completes $20M Expansion of Series C Financing, Increasing Total Round to $105.5M

Continued support of existing investors will fund commercialization efforts, product launch later this year Boulder, CO – April 4, 2019 – Inscripta, a leading gene-editing technology company, today announced that it has increased its previously announced Series C financing with an additional $20 million from existing investors. The new funding adds to the $85.5 million […]

In the First Year of Release, Inscripta’s MAD7 CRISPR Enzyme is Widely Adopted by the Gene-Editing Community

Existing investors contribute an additional $30 million to accelerate tools that will revolutionize genomic research BOULDER, Colo., Dec. 19, 2018 /PRNewswire/ — Inscripta™, a leading gene-editing technology company, today announced that MAD7, its proprietary CRISPR enzyme, has achieved wide adoption by academic, commercial, and government researchers in its first year of availability. MAD7 was recently recognized […]

Twist Bioscience Corporation Announces Pricing of Initial Public Offering

SAN FRANCISCO–(BUSINESS WIRE)–Oct. 30, 2018– Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced that it has priced its initial public offering of 5,000,000 shares of its common stock at a price to the public of $14.00 per share, before underwriting discounts and commissions. […]

10x Genomics Acquires Epinomics

10x Genomics, a leader in the genomics field, today announced its first acquisition with Epinomics, a pioneer in the growing epigenetics space. The acquisition will give 10x Genomics ATAC-seq technology and fundamental IP to accelerate discoveries and further research in epigenomics, paving the way for a new understanding of disease, diagnostics and therapeutics.

10x Genomics Completes $50 Million Series D Financing and $75M Credit Facility

10x Genomics, a company focused on accelerating genomic discovery, today announced that it had raised $125 million in funding. The funding included a $50 million Series D financing. It was led by Meritech Capital Partners and included new investor Wells Fargo Strategic Capital along with current investors Paladin Capital, Fidelity and the SoftBank Group. The Company complemented this financing with a new $75 million credit facility with Silicon Valley Bank.

Mérieux Développement and Paladin Capital Group co-lead $55.5 million Series C financing into Inscripta, a leading company in the field of gene editing, in preparation for platform expansion and commercial launch.

Investment will accelerate development and commercialization of gene-editing tools including enzymes, reagents, instrumentation, and software   San Francisco, Lyon and Boston, February 28, 2018 – Merieux Developpement and Paladin Capital Group announced the completion of a $55.5 million Series C funding into Inscripta, a leading gene-editing technology company, based in Boulder, CO and Pleasanton, CA. Additional […]

Paladin Capital Group Announces Acquisition of PhishMe by Private Equity Syndicate

Paladin Capital Group – a multi-stage investment firm focused on cybersecurity – announced the successful realization of its investment in PhishMe, the industry leader in human-enabled cyber defense solutions, to a syndicate of investors led by BlackRock and Pamplona Capital Management. With a deal valuing PhishMe at around $400 million, the exit represents the largest in the field of human-enabled cyber defense.

Muse bio secures $23M Series B financing led by Venrock

Muse bio, a privately-held company leading the development of next-generation genome engineering capabilities, today announced the completion of a $23 million Series B financing. The oversubscribed financing was led by Venrock and included investments from Foresite Capital and Paladin Capital as well as both Series A investors, NanoDimension and Spruce/MLS.

10x Genomics Completes $55 Million Series C Financing

10x Genomics, a company focused on improving and broadening the application of genomic information today announced the close of a $55 million Series C financing. The financing round was led by Fidelity Management & Research Company and included additional new investors Softbank and JS Capital Management LLC, alongside founding investors Venrock, Foresite Capital, and Paladin Capital.

Twist Bioscience Completes $61 Million Series D Financing and $20 Million Debt Facility

Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced the completion of a $61 million Series D private financing. Crossover participants in the round include ARCH Overage Fund, Merieux Developpement, Cormorant Asset Management LLC, Fidelity Management and Research Company and Foresite Capital Management LLC. Additional investors include ARCH Venture Partners, WuXi Healthcare Ventures, Illumina, Inc., Nick and Joby Pritzker (through their family’s firm Tao Invest), Paladin Capital Group, Yuri Milner, Boris Nikolic and additional strategic corporate and venture investors.

Emily Leproust Of Twist Bioscience Named 2015 Global Thinker By Foreign Policy Magazine

Twist Bioscience, a company focused on synthetic DNA, today announced that its CEO, Emily Leproust, Ph.D., has been selected as one of Foreign Policy’s 100 Leading Global Thinkers of 2015 for fast-tracking the building blocks of life. Each year, Foreign Policy selects the leading Global Thinkers whose contributions and work have changed lives and are shaping the world.

Twist Bioscience Raises $37 Million In Oversubscribed Series C Financing

Twist Bioscience, a company focused on synthetic DNA, today announced the completion of a $37 million Series C financing. Led by Illumina, Inc., participants in the round include new investors Fidelity Management and Research Company and Foresite Capital Management LLC, as well as all existing investors including Nick and Joby Pritzker (through their family’s firm Tao Invest), ARCH Venture Partners, Paladin Capital Group, Yuri Milner, and additional strategic corporate and venture investors.

Paladin Completes Successful Exit of Biofuels Investment

Paladin Capital Group has completed a successful exit of its 49.9% ownership stake in Guardian Lima Holdings, a joint venture of a 60 million gallon per year biofuel production facility located in Lima, Ohio. Paladin’s stake in the joint venture was purchased by Guardian Energy Holdings, the 50.1% owner and strategic partner in the joint venture. With the closing of the transaction, Guardian Energy now owns 100% of the facility.

10X Genomics Closes $55.5 Million Series B Round

10X Genomics, a provider of an innovative genomics platform, today announced that it has raised $55.5 Million in its Series B financing. Foresite Capital Management led the B round and was joined by the Series A lead, Venrock, as well as new and existing investors, including Paladin Capital Group and funds managed by Morgan Stanley Investment Management. To date, the company has raised a total of more than $80M.

Twist Bioscience Secures $31.1 Million

Twist Bioscience today announced that it raised $26 million in a Series B financing to commercialize the company’s semiconductor-based synthetic gene manufacturing process. Nick and Joby Pritzker, through their family’s firm Tao Invest, led the round, with participation from ARCH Venture Partners, Paladin Capital Group, Yuri Milner and additional strategic corporate and venture investors.

Paladin Capital Group Promotions: Dr. Paul Conley to Managing Director

Paladin Capital Group, a leading multi-stage private equity firm based in Washington D.C., is pleased to announce the promotion of Dr. Paul Conley to Managing Director. Dr. Conley possesses a broad set of skills and deep experience base as an investor, entrepreneur and technologist and has been a key principal leading new investments for the firm.

Paladin Capital Group Marks Another Successful Exit in Sale of QuantaLife

QuantaLife, one of the nation’s most promising life sciences companies, was purchased this week by Bio-Rad Laboratories for $162 million – marking another successful exit for Paladin Capital Group. Paladin helped nurture QuantaLife from a tiny startup with a great idea to a dynamic company that is helping to accelerate the search for causes, cures and diagnostics for many important diseases, including cancer, HIV and genetic birth defects.